Home LiteratureArticle Details
PMID: 1744579 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41.

The Journal of experimental medicine ·Vol. 174 ·No. 6 ·1991-12-01 ·Pages 1417-24

Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP

Abstract

Human immunodeficiency virus type 1 (HIV-1), in contrast to animal retroviruses such as murine leukemia virus, is not lysed by human complement. Nevertheless, HIV-1 activates complement via the classical pathway independent of antibody, and C3b deposition facilitates infection of complement receptor-bearing cells. Using gel exclusion chromatography on Sephacryl S-1000, purified virions were found to bind 125I-labeled C1q, but not 125I-labeled dimeric proenzyme C1s. Virions activated the C1 complex, reconstituted from C1q, proenzyme C1r, and 125I-labeled proenzyme C1s, to an extent comparable with that obtained with immunoglobulin G-ovalbumin immune complexes. To determine the activating viral component, recombinant viral proteins were used: in the solid phase, soluble gp41 (sgp41) (the outer membrane part of gp41, residues 539-684 of gp160) bound C1q, but not dimeric proenzyme C1s, while gp120 was ineffective. In the fluid phase, sgp41 activated the C1 complex in a dose- and time-dependent manner, more efficiently than aggregated Ig, but less efficiently than immune complexes. To localize the C1 activating site(s) in gp41, synthetic peptides (15-residue oligomers spanning amino acids 531-695 of gp160) were used. Peptides covering positions 591-605 and 601-620 and, to a lesser extent, positions 561-575, had both the ability to bind C1q and to induce C3 deposition. These data provide the first experimental evidence of a direct interaction between the C1 complex and HIV-1, and indicate that C1 binding and activation are mediated by specific sites in gp41.

MeSH Terms
Binding Sites Complement C1/metabolism Complement Pathway, Classical HIV Envelope Protein gp120/metabolism HIV Envelope Protein gp41/metabolism HIV-1/pathogenicity,physiology Humans Polymyxin B/pharmacology Recombinant Proteins/metabolism
Chemicals
Complement C1 HIV Envelope Protein gp120 HIV Envelope Protein gp41 Recombinant Proteins Polymyxin B
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Ebenbichler C F
Institut für Hygiene, Innsbruck, Austria.
Thielens N M
Vornhagen R
Marschang P
Arlaud G J
Dierich M P
References (55)
55 references, click to expand
  1. Epstein-Barr virus regulates activation and processing of the third component of complement.
    J Exp Med. 1988 Sep 1;168(3):949-69 PMID: 2844953
  2. Reversible binding of Pi by beef heart mitochondrial adenosine triphosphatase.
    J Biol Chem. 1977 May 10;252(9):2891-9 PMID: 16006
  3. HIV and HIV-infected cells differentially activate the human complement system independent of antibody.
    Immunol Lett. 1989 Aug;22(2):135-45 PMID: 2789186
  4. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.
    J Immunol. 1988 Jun 1;140(11):3867-74 PMID: 2836501
  5. The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum.
    Virology. 1986 Jul 15;152(1):268-71 PMID: 3012872
  6. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry.
    Science. 1988 Oct 28;242(4878):580-3 PMID: 2972065
  7. Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects.
    Proc Natl Acad Sci U S A. 1988 Jul;85(14):5225-9 PMID: 2455899
  8. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus.
    J Virol. 1987 Aug;61(8):2639-41 PMID: 2439707
  9. Binding and activation of the first component of human complement by the lipid A region of lipopolysaccharides.
    J Immunol. 1978 Jun;120(6):1862-8 PMID: 351060
  10. Lysis of oncornaviruses by human serum. Isolation of the viral complement (C1) receptor and identification as p15E.
    J Exp Med. 1978 Mar 1;147(3):844-53 PMID: 632750
  11. Human serum lyses RNA tumour viruses.
    Nature. 1975 Oct 16;257(5527):612-4 PMID: 170540
  12. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  13. Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions.
    J Virol. 1987 Feb;61(2):570-8 PMID: 2433466
  14. Complete nucleotide sequence of the AIDS virus, HTLV-III.
    Nature. 1985 Jan 24-30;313(6000):277-84 PMID: 2578615
  15. Complement receptors: another port of entry for HIV.
    Lancet. 1989 Jul 29;2(8657):271-2 PMID: 2569072
  16. HIV infection of monocytic cells: rôle of antibody-mediated virus binding to Fc-gamma receptors.
    AIDS. 1989 Mar;3(3):125-33 PMID: 2523711
  17. Studies with crosslinking reagents on the oligomeric structure of the env glycoprotein of HIV.
    Virology. 1989 Sep;172(1):367-9 PMID: 2672564
  18. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1.
    J Virol. 1989 Jun;63(6):2674-9 PMID: 2786089
  19. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.
    Lancet. 1988 Apr 9;1(8589):790-4 PMID: 2895317
  20. The binding site for C1q on IgG.
    Nature. 1988 Apr 21;332(6166):738-40 PMID: 3258649
  21. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.
    Science. 1987 Sep 11;237(4820):1351-5 PMID: 3629244
  22. Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines.
    Proc Natl Acad Sci U S A. 1985 Feb;82(3):859-63 PMID: 3871945
  23. Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus.
    J Virol. 1990 Oct;64(10):5223-5 PMID: 2168999
  24. Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells.
    J Exp Med. 1990 May 1;171(5):1791-6 PMID: 2159052
  25. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.
    J Exp Med. 1991 Aug 1;174(2):407-15 PMID: 1713252
  26. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro.
    J Virol. 1990 Nov;64(11):5301-5 PMID: 1698995
  27. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection.
    AIDS. 1991 Mar;5(3):263-8 PMID: 1676275
  28. Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line.
    J Virol. 1991 Jan;65(1):541-5 PMID: 1845908
  29. Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion.
    J Exp Med. 1991 May 1;173(5):1151-8 PMID: 1827139
  30. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation.
    AIDS. 1991 Mar;5(3):269-74 PMID: 1829367
  31. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
    J Virol. 1991 Feb;65(2):852-60 PMID: 1898972
  32. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.
    J Virol. 1991 Mar;65(3):1133-40 PMID: 1995942
  33. The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host's previous exposure to similar epitopes on unrelated antigens.
    J Gen Virol. 1990 Sep;71 ( Pt 9):1975-83 PMID: 2170568
  34. Interaction of complement with HIV-1 and Candida albicans: molecular mechanisms and biological implications.
    Mol Immunol. 1990 Dec;27(12):1349-53 PMID: 2274064
  35. Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell line U937.
    AIDS. 1990 Oct;4(10):961-5 PMID: 2261126
  36. Dissociation of gp120 from HIV-1 virions induced by soluble CD4.
    Science. 1990 Nov 23;250(4984):1139-42 PMID: 2251501
  37. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins.
    Nature. 1988 Sep 8;335(6186):176-8 PMID: 3412473
  38. HIV susceptibility conferred to human fibroblasts by cytomegalovirus-induced Fc receptor.
    Nature. 1990 Feb 15;343(6259):659-61 PMID: 2154697
  39. Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques.
    J Virol. 1990 Jan;64(1):113-9 PMID: 2152808
  40. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.
    Proc Natl Acad Sci U S A. 1990 Jun;87(12):4650-4 PMID: 2191297
  41. Ca2+ binding properties and Ca2(+)-dependent interactions of the isolated NH2-terminal alpha fragments of human complement proteases C1-r and C1-s.
    J Biol Chem. 1990 Aug 25;265(24):14469-75 PMID: 2387866
  42. Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors.
    Virology. 1990 Apr;175(2):600-4 PMID: 2327077
  43. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.
    Proc Natl Acad Sci U S A. 1990 Apr;87(8):3185-9 PMID: 2326277
  44. Heat-labile, complement-like factor(s) of animal sera prevent(s) HIV-1 infectivity in vitro.
    J Acquir Immune Defic Syndr. 1990;3(4):366-71 PMID: 2313562
  45. Purification and radiolabeling of human C1q.
    J Immunol. 1981 Aug;127(2):648-53 PMID: 7252154
  46. Human T-cell leukaemia virus is not lysed by human serum.
    Nature. 1984 Jul 26-Aug 1;310(5975):324-5 PMID: 6205277
  47. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells.
    Nature. 1984 Jun 14-20;309(5969):633-5 PMID: 6328323
  48. Purified proenzyme C1r. Some characteristics of its activation and subsequent proteolytic cleavage.
    Biochim Biophys Acta. 1980 Nov 6;616(1):116-29 PMID: 6254570
  49. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.
    J Immunol. 1982 Jul;129(1):184-9 PMID: 6211481
  50. Mechanism of antibody-independent activation of the first component of complement (Cl) on retrovirus membranes.
    Biochemistry. 1980 Jun 24;19(13):2847-53 PMID: 6772208
  51. Dimeric, trimeric and tetrameric complexes of immunoglobulin G fix complement.
    Biochem J. 1980 Jun 1;187(3):775-80 PMID: 6985362
  52. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway.
    J Exp Med. 1976 Oct 1;144(4):970-84 PMID: 62019
  53. Inactivation of lysis of oncornaviruses by human serum.
    Virology. 1976 Oct 15;74(2):432-40 PMID: 62448
  54. Differential elution of Clq, Clr and Cls from human Cl bound to immune aggregates. Use in the rapid purification of Cl subcomponents.
    Mol Immunol. 1979 Jul;16(7):445-50 PMID: 40870
  55. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells.
    Science. 1989 Jun 16;244(4910):1357-60 PMID: 2786647
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1991-12-01
Pages
1417-24
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2119058
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com